Compare Mongodb Inc (MDB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Novartis AG — how do they compare? Mongodb Inc trades at $309.39 (market cap $26.01B), while Novartis AG trades at $154.61 (market cap $290.25B). The key difference: Novartis AG is far larger — about 11.2× Mongodb Inc's market cap, and Novartis AG pays a 3.17% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| MDB | NVS | |
|---|---|---|
Market Cap | $26.01B | $290.25B |
Sector | Technology | Health |
52-Week High | $440.25 | $168.62 |
52-Week Low | $201.08 | $113.50 |
Enterprise Value | $23.61B | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $324.44, up 3.88% today, with strong analyst support (82% buy ratings) and a $400.39 consensus price target. The stock shows bearish technical signals but has consistently beaten earnings expectations, with Q1 2026 EPS of $1.32 surpassing the $1.19 estimate. Revenue growth remains robust at $2.01B for 2025, though profitability challenges persist with a negative net margin of -1.12%.
MDB presents a growth investment opportunity with accelerating revenue and improving margins, but faces execution risks and competitive pressures. The stock's premium valuation (P/S 9.77) requires sustained high growth, while negative cash flow and ongoing profitability concerns warrant caution despite Wall Street optimism.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
